Vir Biotechnology Inc (VIR)
6.95
+0.21
(+3.12%)
USD |
NASDAQ |
Nov 21, 16:00
6.965
+0.02
(+0.22%)
After-Hours: 20:00
Vir Biotechnology Debt to Equity Ratio: 0.00 for Sept. 30, 2024
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| September 30, 2024 | 0.00 |
| June 30, 2024 | 0.00 |
| March 31, 2024 | 0.00 |
| December 31, 2023 | 0.00 |
| September 30, 2023 | 0.00 |
| June 30, 2023 | 0.00 |
| March 31, 2023 | 0.00 |
| December 31, 2022 | 0.00 |
| September 30, 2022 | 0.00 |
| June 30, 2022 | 0.00 |
| March 31, 2022 | 0.00 |
| December 31, 2021 | 0.00 |
| Date | Value |
|---|---|
| September 30, 2021 | 0.00 |
| June 30, 2021 | 0.00 |
| March 31, 2021 | 0.00 |
| December 31, 2020 | 0.00 |
| September 30, 2020 | 0.00 |
| June 30, 2020 | 0.00 |
| March 31, 2020 | 0.00 |
| December 31, 2019 | 0.00 |
| September 30, 2019 | 0.00 |
| June 30, 2019 | 0.00 |
| March 31, 2019 | |
| December 31, 2018 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
Dec 2019
--
Maximum
Dec 2019
--
Average
--
Median
Dec 2019
Debt to Equity Ratio Benchmarks
| Pfizer Inc | 0.7219 |
| Biomarin Pharmaceutical Inc | 0.1098 |
| Arbutus Biopharma Corp | 0.00 |
| GlycoMimetics Inc | -- |
| FibroGen Inc | -0.2987 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 1.498B |
| Total Liabilities (Quarterly) | 257.63M |
| Shareholders Equity (Quarterly) | 1.241B |
| Current Ratio | 8.938 |